At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
In Brief
A Phase 2 clinical trial evaluating Dendritic Cell Tumor Fusion Vaccine and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) for Renal Cancer. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). Another purpose is to determine the type and severity of any side effects associated with this study vaccine. GM-CSF is similar to a substance in the body that stimulates the production of white blood cells. To create the study vaccine, cells will be removed from the participants tumor and fused with dendritic cells which are obtained from the participants blood. Dendritic cells are responsible for immune responses to "foreign" substances that enter the body. Animal studies have shown that these fused cells can stimulate powerful anti-tumor responses.
Study Details
Timeline
Interventions
3 vaccinations at three week intervals
Combined with the vaccine in the remaining subjects after the first 6 are enrolled.